<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">JOACP</journal-id><journal-title-group><journal-title>Journal of Anaesthesiology, Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0970-9185</issn><issn pub-type="epub">2231-2730</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28096577</article-id><article-id pub-id-type="pmc">5187611</article-id><article-id pub-id-type="publisher-id">JOACP-32-470</article-id><article-id pub-id-type="doi">10.4103/0970-9185.194778</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effect of atrial natriuretic peptide infusion on intestinal injury in septic shock</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elbaradey</surname><given-names>Ghada F.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Elshmaa</surname><given-names>Nagat Sayed</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Hodeib</surname><given-names>Hossam</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1">Department of Anesthesia and Surgical ICU, Faculty of Medicine, Tanta University, Tanta, Egypt</aff><aff id="aff2"><label>1</label>Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Nagat S. Elshmaa, Department of Anesthesia and Surgical ICU, Faculty of Medicine, Tanta University, Tanta, Egypt. E-mail: <email xlink:href="nagat_elshmaa@yahoo.com">nagat_elshmaa@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2016</year></pub-date><volume>32</volume><issue>4</issue><fpage>470</fpage><lpage>475</lpage><permissions><copyright-statement>Copyright: &#x000a9; Journal of Anaesthesiology Clinical Pharmacology</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background and Aims:</title><p>The aim of this study is to assess the effect of atrial natriuretic peptide (ANP) on intestinal ischemia-reperfusion injury in septic shock.</p></sec><sec id="st2"><title>Material and Methods:</title><p>A prospective randomized controlled, observer-blinded study was carried out in surgical Intensive Care Unit (ICU), University Hospital. Forty adult patients in septic shock were randomly divided into two groups, control group (Group C) received normal saline and ANP group (Group A) patients received ANP in the form of 1.5 mg vial added to 250 ml solvent in plastic bag (1 ml = 6 micg) given at 2 mcg/kg intravenous bolus over 1 min followed by 0.01 mcg/kg/min for 24 h. The primary outcome measurements were blood marker of intestinal hypoperfusion in form of intestinal fatty acid binding protein (I-FABP), malondialdehyde (MDA), myloperoxidase enzyme activity (MPO), protein carbonyl (PC), and glutathione peroxidase activity (GPA) measured before start of ANP infusion, 6 h, 12 h, and 24 h after start of infusion. The secondary outcome measurements were the duration of noradrenaline infusion, duration of ICU stay, hospital mortality rate, and complications related to ANP.</p></sec><sec id="st3"><title>Results:</title><p>In comparison with Group C, Group A showed a significant decrease (<italic>P</italic> &#x0003c; 0.05) in serum level of MPO, MDA, PC, and I-FABP, with a significant increase (<italic>P</italic> &#x0003c; 0.05) in serum level of GPA, 6 h, 12 h, and 24 h after the start of ANP infusion. There was significant decrease (<italic>P</italic> &#x0003c; 0.05) in mean duration of noradrenaline infusion, the length of ICU stay and mortality rate in Group A in comparison with Group C. In Group A, seven patients had mean arterial blood pressure &#x0003c; 65 mmHg but respond to volume resuscitation, three patients serum sodium was 125&#x02013;130 mmol/L.</p></sec><sec id="st4"><title>Conclusion:</title><p>In cases of septic shock, concomitant administration of ANP with noradrenaline may have a protective effect against intestinal injury through a decrease in the level of intestinal hypoperfusion owing to its anti-inflammatory and antioxidant effect.</p></sec></abstract><kwd-group><title>Key words</title><kwd>Atrial natriuretic peptide</kwd><kwd>chemical markers</kwd><kwd>Intensive Care Unit</kwd><kwd>ischemia-reperfusion injury</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Severe trauma and major surgery frequently result in the development of inflammatory complications, including systemic inflammatory response syndrome, sepsis, and septic shock with subsequent splanchnic hypoperfusion. Intestinal cell damage developed within 1 h after shock induction.[<xref rid="ref1" ref-type="bibr">1</xref>]</p><p>Tissue injury after ischemia is primarily caused by reduced oxygen supply and the injury may be worsened during reperfusion phase via formation of reactive oxygen radicals which can promote cell destruction and bowel necrosis through peroxidation of membrane lipid with subsequent increase in the intestinal mucosal level of malondialdehyde (MDA).[<xref rid="ref2" ref-type="bibr">2</xref>] In addition, membrane protein oxidation induces early increase in mucosal protein carbonyl (PC) level owing to formation of reactive chlorinating species capable of oxidizing protein. Moreover, the oxidative stress inhibit the endogenous antioxidant system which includes glutathione peroxidase and superoxide dismutase.[<xref rid="ref3" ref-type="bibr">3</xref>]</p><p>Intestinal fatty acid binding protein (I-FABP), a cytosolic protein distributes in the small bowel mucosa from the duodenum to the distal segment of the ileum, and its serum level elevates rapidly at the early stages of small bowel ischemia. Hence, it is considered as an early biomarker for intestinal disease, ischemia, and damage.[<xref rid="ref4" ref-type="bibr">4</xref>]</p><p>Ischemia stimulates localized infiltration of activated neutrophils which is manifested by significant increase in the mucosal level of myloperoxidase enzyme activity (MPO).[<xref rid="ref5" ref-type="bibr">5</xref>]</p><p>Research in this field has identified key molecular and signaling players that could modulate the tissue injury during this disease process. However, further elucidation of the molecular mechanisms should provide the rationale to identify much needed novel therapeutic options to ameliorate organ damage.[<xref rid="ref6" ref-type="bibr">6</xref>]</p><p>Atrial natriuretic peptide (ANP) besides its role in regulating volume homeostasis, has a protective effect during ischemia-reperfusion injury (IRI) in many tissues. Recent research documented anti-inflammatory, antifibrotic, and antimitogenic actions for NPs. Based on the multiple protective effects of NPs, it was approved for use in the United States in 2001 by the Food and Drug Administration for acute decompensated heart failure. A previous study demonstrated protective effect of NP in IRI in heart, lung, brain, and liver owing to the extracardiac expression for NP receptors.[<xref rid="ref7" ref-type="bibr">7</xref>] Hence, in this work, we attempted to evaluate the role of ANP in attenuating intestinal injury in septic shock.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Material and Methods</title><p>This is a prospective observer-blinded study carried out in surgical Intensive Care Unit (ICU) from March 2013 to April 2014 on 40 patients in septic shock after approval by Hospital Ethical Committee. The CONSORT 2010 statement was followed in reporting this study.</p><sec id="sec2-1"><title>Inclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Patients in septic shock according to the American college of chest physicians/society of critical care medicine definitions,[<xref rid="ref8" ref-type="bibr">8</xref>] which include strongly suspected infection or positive blood culture plus persistent hypotension despite adequate fluid resuscitation requiring vasopressors to maintain mean arterial blood pressure (MAP) &#x02265;65 mmHg, and lactate &#x02265;2 mmol/L</p></list-item><list-item><p>Patients were treated with antibiotics according to blood culture and sensitivity test</p></list-item><list-item><p>Patients on vasopressor noradrenaline intravenous (IV) infusion (0.05&#x02013;0.2 micg/kg/min)</p></list-item><list-item><p>MAP &#x02265;65 mmHg.</p></list-item></list>
</p></sec><sec id="sec2-2"><title>Exclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Patients on noradrenaline dose &#x0003e;0.2 micg/kg/min</p></list-item><list-item><p>Patients with electrolyte imbalance</p></list-item><list-item><p>Patients with one or more organ failure</p></list-item><list-item><p>Patients with renal dysfunction</p></list-item><list-item><p>Patients with valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, and pericardial tamponade.</p></list-item></list>
</p><p>Randomization was performed through a computer-generated, random number list. The random number list was generated using the QuickCalcs (GraphPad Software Inc., La Jolla, CA, USA). The group assignment numbers were sealed in an envelope and kept by the study supervisor. After admission to ICU, a written informed consent was obtained from the nearest relatives. Patients were randomly divided into two groups of twenty patients each.</p><p>Group (C): Control group received normal saline.</p><p>Group (E): patients received ANP (Natrecor Scios Inc., Titusville, NJ 08560, Austria)) supplied from Sigma company in form of 1.5 mg vial added to 250 ml plastic IV bag (1 ml = 6 mg) given at 2 mcg/kg IV bolus over 1 min followed by 0.01 mcg/kg/min for 24 h (the dose approved for acute decompensated heart failure).[<xref rid="ref7" ref-type="bibr">7</xref>]</p><p>Patients were monitored for mean arterial pressure (MAP) (mmHg), heart rate (HR) (b/min), central venous pressure (CVP) (cmH<sub>2</sub>O), temperature, urine output (UOP), total fluid balance and routine investigation (complete blood count, arterial blood gases, serum electrolytes, liver, and kidney function).</p></sec><sec id="sec2-3"><title>Measurements</title><p>The primary outcome measurements were blood marker of intestinal hypoperfusion in the form of the following laboratory data which was measured before the start of ANP infusion, 6 h, 12 h and 24 h after the start of infusion. Blood sample (5 ml) was centrifuged and serum was used to measure:</p><p>
<list list-type="bullet"><list-item><p>I-FABP as a marker of intestinal ischemia using (ELISA) measured by spectrophotometer at wavelength 450 nm[<xref rid="ref9" ref-type="bibr">9</xref>]</p></list-item><list-item><p>MDA measured by spectrophotometer at wavelength 535 nm[<xref rid="ref10" ref-type="bibr">10</xref>]</p></list-item><list-item><p>PC level measured by spectrophotometer at wavelength 366 nm[<xref rid="ref11" ref-type="bibr">11</xref>]</p></list-item><list-item><p>MPO measured by spectrophotometer at wavelength 655 nm[<xref rid="ref12" ref-type="bibr">12</xref>]</p></list-item><list-item><p>Glutathione peroxidase activity (GPA) (lipid peroxide scavenger) was expressed as nanomols of reduced nicotinamide adenine dinucleotide phosphate oxidized to NADH measured by spectrophotometer at wavelength 340 nm.[<xref rid="ref13" ref-type="bibr">13</xref>]</p></list-item></list>
</p><p>The secondary outcome measurements were the duration of noradrenaline infusion (days), duration of ICU stay, hospital mortality rate and complications related to ANP such as hypotension, headache, nausea, and back pain.(if developed during time of the study, the drug infusion was stopped, and complication was recorded).</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>Sample size of forty patients was calculated for 90% power, &#x003b1; =0.05, &#x003b2; =0.1, and anticipated effect size = 0.40 using sample size software (G * Power Version 3.00.10, Germany). Analytic statistics was performed on IBM compatible computer using SPSS 11.5 (SPSS Inc., Chicago, IL, USA) under Windows XP operating system. All results presented in the form of mean &#x000b1; standard deviation. Data compared using unpaired Student's <italic>t</italic>-test; <italic>P</italic> &#x0003c; 0.05 was considered as statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p><xref ref-type="fig" rid="F1">Figure 1</xref> shows the flow diagram for this study, in which 52 patients were assessed for eligibility and 40 adult patients were included in the study. The results of 40 adult patients were analyzed.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>The trial flow diagram, including enrollment, intervention allocation, and analysis</p></caption><graphic xlink:href="JOACP-32-470-g001"/></fig><p>There was no significant difference between both groups as regard patients characteristics and disease severity [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patients characteristics</p></caption><graphic xlink:href="JOACP-32-470-g002"/></table-wrap><p>In comparison with Group C, Group A showed a significant decrease (<italic>P</italic> &#x0003c; 0.05) in serum level of MPO, MDA, PC, and I-FABP, with a significant increase (<italic>P</italic> &#x0003c; 0.05) in serum level of GPA 6 h, 12 h and 24 h after the start of ANP infusion [<xref ref-type="table" rid="T2">Table 2</xref>]. There was significant decrease (<italic>P</italic> &#x0003c; 0.05) in mean duration of noradrenaline infusion, the length of ICU stay and hospital mortality rate in group A in comparison with Group C [<xref ref-type="table" rid="T3">Table 3</xref>]. In Group A, after 12 h of ANP infusion, there was significant decrease (<italic>P</italic> &#x0003c; 0.05) in MAP, CVP, HR, and serum sodium with a significant increase (<italic>P</italic> &#x0003c; 0.05) in UOP [<xref ref-type="table" rid="T4">Table 4</xref>]. Seven patients had MAP &#x0003c;65 mmHg but respond to volume resuscitation with insignificant change in noradrenaline dose, three patients serum sodium was 125&#x02013;130 mmol/L.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Primary outcomes variables</p></caption><graphic xlink:href="JOACP-32-470-g003"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Secondary outcome variables</p></caption><graphic xlink:href="JOACP-32-470-g004"/></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Patients data during atrial natriuretic infusion</p></caption><graphic xlink:href="JOACP-32-470-g005"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>Tissue perfusion following a period of hypoperfusion represents complex series of events during shock. In this study, before administration of ANP, there was a significant increase in serum level of MDA, PC, MPO, and I-FABP with a significant decrease in serum GP activity. These results could be attributed to the generation of reactive oxygen species which are generated when oxygen is reintroduced to xanthine oxidase enzyme activation during ischemia. These potentially toxic reactive oxygen species can promote cell destruction and bowel necrosis through peroxidation of membrane lipid and protein manifested in this study by a significant increase in serum level of MDA and PC.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>The intestine is one of the richest sources in the body of xanthine oxidase enzyme that exhibit a gradient of increasing activity which play a major role in the generation of toxic superoxide radicals. Under normal condition xanthine dehydrogenase form is predominant but during ischemia xanthine dehydrogenase will be oxidized into xanthine oxidase which becomes a major source for toxic superoxide radical production once the tissues are reperfused and oxygen is reintroduced.[<xref rid="ref15" ref-type="bibr">15</xref>]</p><p>Moreover, the reactive oxygen species could stimulate localized infiltration of activated neutrophils which is demonstrated in this work by a significant increase in serum level of MPO which in turn is a potential source for further release of reactive oxygen radicals with enhanced secretion of proinflammatory cytokines by mast cells and macrophages. The inflammatory cytokines leading to the formation of reactive chlorinating species capable of oxidizing protein with a subsequent increase in plasma PC level.[<xref rid="ref16" ref-type="bibr">16</xref>]</p><p>This work demonstrated that IV infusion of ANP for 24 h recorded a significant decrease in serum level of MDA, PC, MPO, and IFAP with a significant increase in serum GP activity in comparison with control group.</p><p>ANP and its receptors were demonstrated to be expressed in diverse tissues beside the cardiovascular and renal system. Many previous studies recorded significant antioxidant and anti-inflammatory effects of ANP in many tissues.[<xref rid="ref7" ref-type="bibr">7</xref>]</p><p>The initial signaling events responsible for the protective potential of ANP are still unknown. Some studies reported ANP could attenuate activation of nuclear factor kappa B in macrophages. The reduced binding activity of this redox-sensitive transcription factor was accompanied by diminished m RNA expression of tumor necrotizing factor alpha chemokines and cell adhesion molecules thereby reducing leukocytes infiltration manifested in this study by a significant decrease in the serum level of MPO.[<xref rid="ref5" ref-type="bibr">5</xref>]</p><p>FABP is one of the intracellular proteins that plays important role in transportation and metabolism of long-chain fatty acids which is rapidly released into circulation just after small intestinal mucosal injury.[<xref rid="ref4" ref-type="bibr">4</xref>]</p><p>Alexandra <italic>et al</italic>.[<xref rid="ref17" ref-type="bibr">17</xref>] stated that ANP could inhibit the activity of inducible NO synthetase (iNOS) in macrophages via destabilization of iNOS mRNA and this protective effects of ANP are mediated by cyclic guanosine monophosphate. Inhibition of NO formation will inhibit the reactive oxygen species and hence inhibit lipid and protein peroxidation manifested in this work by a significant decrease in serum level of MDA and PC.</p><p>In addition, this study shows that ANP induces significant increase in serum GP activity. Chujo <italic>et al</italic>.[<xref rid="ref18" ref-type="bibr">18</xref>] stated that ANP could stimulate the antioxidant defense system or may induce antioxidant activity by itself.</p><p>Aoyama <italic>et al</italic>.[<xref rid="ref19" ref-type="bibr">19</xref>] revealed that administration of ANP infusion at the onset of lung reperfusion attenuates reperfusion injury.</p><p>Chujo <italic>et al</italic>. and Moriyama <italic>et al</italic>.[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref>] found that ANP attenuates ischemia-reperfusion in induced renal failure through inhibition of inflammatory mediators, MPO and neutrophils activation when given as IV infusion for 2 h after reperfusion injury.</p><p>Yamada <italic>et al</italic>.[<xref rid="ref22" ref-type="bibr">22</xref>] found the protective effect to ANP in hepatic ischemia-reperfusion.</p></sec><sec sec-type="conclusions" id="sec1-5"><title>Conclusion</title><p>In cases of septic shock, concomitant administration of ANP with noradrenaline may have a protective effect against intestinal injury through a decrease in the level of intestinal hypoperfusion markers owing to its anti-inflammatory and antioxidant effect.</p><sec id="sec2-5"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-6" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank the nurses at the surgical ICU of Tanta University Hospital, Tanta; for their assistance in conducting the study.</p></ack><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Haan</surname><given-names>JJ</given-names></name><name><surname>Lubbers</surname><given-names>T</given-names></name><name><surname>Derikx</surname><given-names>JP</given-names></name><name><surname>Relja</surname><given-names>B</given-names></name><name><surname>Henrich</surname><given-names>D</given-names></name><name><surname>Greve</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Rapid development of intestinal cell damage following severe trauma: A prospective observational cohort study</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R86</fpage><pub-id pub-id-type="pmid">19505335</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collard</surname><given-names>CD</given-names></name><name><surname>Gelman</surname><given-names>S</given-names></name></person-group><article-title>Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury</article-title><source>Anesthesiology</source><year>2001</year><volume>94</volume><fpage>1133</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11465607</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamel</surname><given-names>MJ</given-names></name><name><surname>Pereira Lde</surname><given-names>P</given-names></name><name><surname>Mello</surname><given-names>NB</given-names></name><name><surname>Eleuth&#x000e9;rio</surname><given-names>EC</given-names></name><name><surname>Schanaider</surname><given-names>A</given-names></name></person-group><article-title>Blood carbonyl protein measurement as a specific oxidative stress biomarker after intestinal reperfusion in rats</article-title><source>Acta Cir Bras</source><year>2010</year><volume>25</volume><fpage>59</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">20126890</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Bamba</surname><given-names>T</given-names></name><name><surname>Funaoka</surname><given-names>H</given-names></name><name><surname>Kosugi</surname><given-names>S</given-names></name><name><surname>Yajima</surname><given-names>K</given-names></name><etal/></person-group><article-title>Serum intestinal fatty acid binding protein in patients with small bowel obstruction</article-title><source>Surg Sci</source><year>2013</year><volume>4</volume><fpage>302</fpage><lpage>7</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>P</given-names></name><name><surname>Madsen</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Castillo</surname><given-names>E</given-names></name><name><surname>Avila</surname><given-names>J</given-names></name><name><surname>Lakey</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Alleviating ischemia-reperfusion injury in small bowel</article-title><source>Am J Transplant</source><year>2004</year><volume>4</volume><fpage>728</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">15084167</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>KX</given-names></name><name><surname>Li</surname><given-names>YS</given-names></name><name><surname>Huang</surname><given-names>WQ</given-names></name><name><surname>Chen</surname><given-names>SQ</given-names></name><name><surname>Wang</surname><given-names>ZX</given-names></name><name><surname>Liu</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Immediate postconditioning during reperfusion attenuates intestinal injury</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><fpage>933</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">19190893</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shatsky</surname><given-names>M</given-names></name></person-group><article-title>Nesiritide (natrecor) for acute decompensated heart failure</article-title><source>Am Fam Physician</source><year>2006</year><volume>73</volume><fpage>687</fpage><lpage>8</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><article-title>Sepsis definitions: Time for change</article-title><source>Lancet</source><year>2013</year><volume>381</volume><fpage>774</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23472921</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funaoka</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name></person-group><article-title>Intestinal fatty acid-binding protein (I-FABP) as a new biomarker for intestinal diseases</article-title><source>Rinsho Byori</source><year>2010</year><volume>58</volume><fpage>162</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20229815</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x000fc;k&#x000f6;zkan</surname><given-names>N</given-names></name><name><surname>Erdamar</surname><given-names>H</given-names></name><name><surname>Seven</surname><given-names>I</given-names></name></person-group><article-title>Measurement of total malondialdehyde in plasma and tissues by high-performance liquid chromatography and thiobarbituric acid assay</article-title><source>F&#x00131;rat T&#x00131;p Derg</source><year>2006</year><volume>11</volume><fpage>88</fpage><lpage>92</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>CE</given-names></name><name><surname>Keshavarzian</surname><given-names>A</given-names></name><name><surname>Pasco</surname><given-names>DS</given-names></name><name><surname>Frommel</surname><given-names>TO</given-names></name><name><surname>Winship</surname><given-names>DH</given-names></name><name><surname>Holmes</surname><given-names>EW</given-names></name></person-group><article-title>Determination of protein carbonyl groups by immunoblotting</article-title><source>Anal Biochem</source><year>1999</year><volume>266</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">9887212</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winterbourn</surname><given-names>CC</given-names></name><name><surname>Kettle</surname><given-names>AJ</given-names></name></person-group><article-title>Biomarkers of myeloperoxidase-derived hypochlorous acid</article-title><source>Free Radic Biol Med</source><year>2000</year><volume>29</volume><fpage>403</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11020661</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weydert</surname><given-names>CJ</given-names></name><name><surname>Cullen</surname><given-names>JJ</given-names></name></person-group><article-title>Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue</article-title><source>Nat Protoc</source><year>2010</year><volume>5</volume><fpage>51</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">20057381</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollmar</surname><given-names>B</given-names></name><name><surname>Menger</surname><given-names>MD</given-names></name></person-group><article-title>Intestinal ischemia/reperfusion: Microcirculatory pathology and functional consequences</article-title><source>Langenbecks Arch Surg</source><year>2011</year><volume>396</volume><fpage>13</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">21088974</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grisham</surname><given-names>MB</given-names></name><name><surname>Hernandez</surname><given-names>LA</given-names></name><name><surname>Granger</surname><given-names>DN</given-names></name></person-group><article-title>Xanthine oxidase and neutrophil infiltration in intestinal ischemia</article-title><source>Am J Physiol</source><year>1986</year><volume>251</volume><issue>4 Pt 1</issue><fpage>G567</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">3020994</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Worrell</surname><given-names>RT</given-names></name><name><surname>Pritts</surname><given-names>TA</given-names></name><name><surname>Montrose</surname><given-names>MH</given-names></name></person-group><article-title>Intestinal ischemia-reperfusion injury: Reversible and irreversible damage imaged <italic>in vivo</italic></article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2009</year><volume>297</volume><fpage>G187</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">19407214</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandra</surname><given-names>K</given-names></name><name><surname>Stefanic</surname><given-names>K</given-names></name><name><surname>Tobias</surname><given-names>G</given-names></name><name><surname>Angelika</surname><given-names>M</given-names></name></person-group><article-title>Vasoprotective action of ANP</article-title><source>Curr Med Chem Cardiovasc Hematol Agents</source><year>2005</year><volume>3</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15638740</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chujo</surname><given-names>K</given-names></name><name><surname>Ueki</surname><given-names>M</given-names></name><name><surname>Asaga</surname><given-names>T</given-names></name><name><surname>Taie</surname><given-names>S</given-names></name></person-group><article-title>Atrial natriuretic peptide attenuates ischemia/reperfusion-induced renal injury by reducing neutrophil activation in rats</article-title><source>Tohoku J Exp Med</source><year>2008</year><volume>215</volume><fpage>257</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">18648186</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Fujinaga</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Tsuruyama</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Post-ischemic infusion of atrial natriuretic peptide attenuates warm ischemia-reperfusion injury in rat lung</article-title><source>J Heart Lung Transplant</source><year>2009</year><volume>28</volume><fpage>628</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">19481025</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chujo</surname><given-names>K</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Asaga</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Shirakami</surname><given-names>G</given-names></name><name><surname>Ueki</surname><given-names>M</given-names></name></person-group><article-title>Atrial natriuretic peptide enhances recovery from ischemia/reperfusion-induced renal injury in rats</article-title><source>J Biosci Bioeng</source><year>2010</year><volume>109</volume><fpage>526</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">20471588</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriyama</surname><given-names>T</given-names></name><name><surname>Kanmura</surname><given-names>Y</given-names></name><name><surname>Lindahl</surname><given-names>SG</given-names></name></person-group><article-title>Atrial natriuretic peptide attenuation of renal ischemia-reperfusion injury after major surgery</article-title><source>J Surg Res</source><year>2016</year><volume>201</volume><fpage>213</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26850205</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Kotake</surname><given-names>Y</given-names></name><name><surname>Nagata</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name></person-group><article-title>Atrial natriuretic peptide reduces hepatic ischemia-reperfusion injury in rabbits</article-title><source>J Anesth</source><year>2013</year><volume>27</volume><fpage>901</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23736823</pub-id></element-citation></ref></ref-list></back></article>